Clinical Trial Update: TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 clinical trial evaluating VTX-2337, a TLR8 agonist, in combination with pegylated liposomal doxorubicin hydroc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Pegylated liposomal doxorubicin hydrochloride (pegylated liposomal doxorubicin)
• VTX-2337 (TLR8 agonist)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor | Phase 1 | Status: COMPLETED